Kornimate/medical-research-clean huggingface dataset:
smarter: using blood samples to improve fit-based colorectal cancer screening

Conditions: Colorectal Cancer

Summary: the project aims to investigate whether colorectal cancer screening can be improved using blood tests, thereby reducing the number of unnecessary colonoscopies. the danish colorectal cancer screening program was implemented in 2014, and currently, all individuals aged 50-74 are invited every two years to participate. those who test positive for hidden blood in their stool are referred for a colonoscopy. more than a third of the approximately 25,000 colonoscopies performed annually in the screening program can be classified as unnecessary, as they reveal a normal colon. this results in avoidable and unpleasant procedures for individuals and strains healthcare resources. the project seeks to reduce the number of these unnecessary colonoscopies by investigating whether blood biomarkers can identify individuals at very low risk of colorectal cancer after a positive stool test for hidden blood. by utilizing blood tests, screening could become more personalized, precise, and resource-efficient for the healthcare system.


Eligibility criteria:
inclusion criteria: * participation in the colorectal cancer screening program. exclusion criteria: * participants are excluded if a colonoscopy is not completed unless this is due to a colorectal cancer obstruction.
the effectiveness of the mindfulness-based cognitive therapy (mbct) on sexual functioning in epileptic women

Conditions: Epilepsy; Sexual Dysfunction

Summary: female sexual dysfunction (fsd) includes impairments in sexual desire, arousal, orgasm, and genital pain resulting in significant subjective distress. this study is aimed to assess a mindfulness-based intervention for improving sexual functioning among women with epilepsy


Eligibility criteria:
inclusion criteria: * aged 65 years or older * female sexual dysfunctions are categorized by the dsm-5 as sexual interest/arousal disorder, genitopelvic pain/penetration disorder, and female orgasmic disorder. the diagnoses require symptoms to be present for six months or more, * currently in a relationship that has lasted longer than 1 year * both members of the couple are able to speak and read persian * both members of the couple provide signed and dated informed consent form exclusion criteria: * cognitive impairment or mental illness that would impair ability to provide consent or participate in the program * major psychiatric disorder (e.g., psychosis, personality disorder) * current suicidal ideation or suicide attempt within past 3 months * past participation in an mbct program
lgg for prevention of infectious complications during ppi treatment in children

Conditions: Gastroesophageal Reflux Disease; Gastrointestinal Infections; Respiratory Tract Infections

Summary: background: proton pump inhibitors (ppi) are effective for treating gastroesophageal reflux disease (gerd). however, they may be associated with an increased risk of gastrointestinal and respiratory tract infections. aim: to determine if lactobacillus gg (lgg) is an effective adjunct to ppi for reducing the risk of gastrointestinal and respiratory tract infections in children with gerd. study design: randomized, double-blind, placebo controlled trial.

patients with gerd treated with ppi will be randomly assigned to receive lgg in dose of 10(9) colony forming units (cfu) twice daily for 6 weeks or a comparable placebo twice daily for 6 weeks.

Eligibility criteria:
inclusion criteria: * age \<5, * clinical symptoms of gerd * treatment with proton pump inhibitors * signed informed consent exclusion criteria: * treatment with ppi within the last 4 weeks for at least 2 weeks * administration of probiotics within 7 days prior to the study * acute or chronic respiratory tract infections * acute or chronic gastrointestinal tract infections * neurological disorders * immunodeficiency
cardiac rehabilitation of heart failure patients by telemedicine

Conditions: Heart Failure

Summary: the purpose of the read study is to compare the continuation of the cardiac rehabilitation at home with clinical follow-up, therapeutic education, and advice on the training at the stamina, via telemedicine with the classic strategy in day hospital.


Eligibility criteria:
inclusion criteria: * patient with a dysfunction of left ventricle with ejection fraction of left ventricle \< 40 % appreciated by echocardiogram at hospital discharge for cardiac rehabilitation. exclusion criteria: * patient non authorized to follow an effort training * therapeutic education impossible * pregnant woman or breast-feeding * no assent * incapacity to use the terminal * minor patient or under supervision
hardwins - squamous cell carcinoma head & neck (surgery/rt)

Conditions: Carcinoma, Squamous Cell

Summary: this study is examining the effects of increasing the dose of radiation given to treat head and neck cancer. radiation doses to the primary cancer are higher than usually given; lymph glands of the neck will also be treated at a lower dose. surgery on the lymph glands my be necessary in the future. radiation treatments given in small fractions twice a day allows a higher dose to be delivered than if the treatment was given once a day. this study will enroll patients at three sequential increasing dose levels. approximately 40 patients will be enrolled at each dose level.


Eligibility criteria:
inclusion criteria: * histologically proven squamous cell carcinoma * larynx \& pharynx (except nasopharyngeal carcinoma) * stage iii \& iv, but any stage hypopharynx * informed consent exclusion criteria: -
percutaneous electrolysis, ultrasound-guided percutaneous neuromodulation therapy and eccentric exercise in supraspinatus tendinopathy.

Conditions: Supraspinatus Tendinitis

Summary: the supraspinatus muscle tendinopathy show a big impact, however, there is a lack of awareness about the options of the physiotherapist treatment. it is necessary to do studies about effectiveness of therapeutic percutaneous electrolysis and neuromodulation. this technique enables treatment of the tendinopathies. to analyze the effectiveness of therapeutic percutaneou electrolysis and neuromodulation in the treatment of supraspinatus muscle tendinopathy. single center randomized controlled trial, parallel treatment design. a specialist physician will be diagnosed the supraspinatus muscle tendinopathy. participants will be randomly assigned to receive treatmen for 4 weeks: percutaneou electrolysis and neuromodulation associated with eccentric exercises or conventional treatment of physiotherapy with the same eccentric exercises. both interventions were performed under ultrasound guidance with a portable ultrasound (general electric logice). data will be collected by a blinded evaluator.

eccentric exercises of the supraspinatus muscle were performed in 3 sets of 10 repetitions. participants were asked to perform the exercise program on an individual basis twice every day for 4 weeks. the eccentric program consisted of 3 exercises, focusing on the supraspinatus, infraspinatus, and scapular muscles. participants were asked to do a normal abduction (concentric phase) and a slow return to the initial position (eccentric phase) included first the concentric phase, and the eccentric phase was slowly conducted. the exercise program was taught by a physiotherapist in the first session and monitored in the subsequent sessions.

Eligibility criteria:
inclusion criteria: * patients diagnosed with supraspinatus tendinopathies that do not improve with conventional physiotherapy or pharmacological therapy protocols. * subjects who are in an active state of pain, who present painful symptoms in a sensitive and painful area of the tendon of insertion of the supraspinatus muscle in the humerus. exclusion criteria: * individuals who have received surgery intervention in the same shoulder, or have suffered fractures or dislocations in the same shoulder. * individuals have received the proposed treatment in one month´s period previously. * individuals who suffering from cervical radiculopathies, fibromialgia síndrome, cardiac patients with pacemakers, cancer, infectious processes, or generalized lymphedema. * pregnant women can not receive this treatment intervention.

Keywords: tendinopathy electrolysis exercise dry needling
functional food application of okara protein hydrolysate (oph)- for anti-exercise-fatigue

Conditions: Healthy

Summary: the aim of this study is to investigate the anti-exercise-fatigue effects of okara protein hydrolysate (oph) in men

each subject must undergo a cardiopulmonary capacity test to assess the maximum oxygen uptake 1 week before the intervention (day 1), and then eat the test food for 4 weeks (day 8 to day 35). before and after the intervention (the 8th and 35th day), posture measurement, diet questionnaire survey and endurance exercise ability test were carried out. the trial period was 35 days. the subjects will take blood samples before, during, after, and 30 minutes and 60 minutes after the end of the two endurance exercise tests. during the whole period of participating in the program, blood will be collected 10 times, each with a blood volume of 15 ml. gas is collected during the period and within 1 hour after exercise. gas is collected every 15 minutes and 1 minute at a time. analyze his exercise time, oxygen intake and blood biochemical value.

Eligibility criteria:
inclusion criteria: * the subject is a male and aged 20-40. * the subject has a usual exercise habit (exercising 2 times or more per week) and did not participate in professional sports competitions or professional sports training during the study period. * no smoking or drinking habits. * no food allergies and the liver function is normal. * no cardiovascular diseases or other chronic diseases, and no serious illnesses requiring hospitalization during the study period. * the subject can understand the test process described in the consent form and the possible potential risks and benefits, and can sign the consent form. * the subject can accept dietary control during the trial period. exclusion criteria: * those who have taken nutritional supplements containing branched-chain amino acids. * those who cannot complete the endurance exercise ability test. * those who are diagnosed with kidney disease, heart disease, or cancer and are still under active treatment. * have used other drugs, whose pharmacological effects may affect fatigue. * subjects who have systemic infections and require systemic antibiotics.
topiramate in neonates receiving whole body cooling for hypoxic ischemic encephalopathy

Conditions: Hypoxic Ischemic Encephalopathy

Summary: the goal is to see whether topiramate (an anti-epileptic agent) improves the outcome of babies with neonatal hypoxic encephalopathy who are receiving whole body cooling.

hypoxic ischemic encephalopathy (hie) is a devastating and unexpected disease in newborns that affects 1.5-2.6 per 1000 live births. hypoxic ischemic encephalopathy has a mortality rate of up to 30% and survivors are at significant risk for adverse long-term outcomes, including seizures, cerebral palsy, and developmental delay. the investigators propose a randomized controlled study comparing therapeutic hypothermia alone, or therapeutic hypothermia combined with topiramate. the investigators hypothesize that adjuvant therapy with topiramate will reduce short term severity of hie including seizures (the primary outcome), a composite hie severity score, and reduce the time of normalization of the amplitude integrated eeg (aeeg). the investigators further hypothesize, that it will improve longer term outcomes such as developmental outcome. the primary hypothesis is that seizures before hospital discharge (or before 4 weeks post-natal age (which ever is earlier)) will be significantly reduced in the topiramate group compared to the control group

Eligibility criteria:
inclusion criteria: in order to be eligible for cooling the baby must meet all three of the following sets of criteria 1. be near term (typically ≥34wks gestation) and be aged \< 6h old 2. have signs of early perinatal depression (either 10 minute apgar score \< 5, or ph \< 7.00 within 60mins of age, or base excess \< -12 within 60mins of age, or need respiratory support at 10min of age due to respiratory depression) 3. have signs of moderate or severe encephalopathy based on either clinical examination or on amplitude integrated aeeg assessment exclusion criteria: 1. known congenital myopathy 2. known congenital neuropathy

Keywords: hypoxic ischemic encephalopathy hie perinatal depression whole body cooling therapeutic hypothermia
multiple ascending dose study of bms-777607 in subjects with advanced or metastatic solid tumors

Conditions: Advanced Solid Tumors

Summary: part a: the purpose of this study is to find the maximum tolerated dose of bms-777607 in subjects with advanced or metastatic solid tumors part b: the purpose of this study is to describe the preliminary activity of bms-77607 in subjects with advanced or metastatic gastroesophageal cancer, hormone refractory prostate cancer, head and neck squamous cell carcinoma, and type i papillary renal cell carcinoma


Eligibility criteria:
inclusion criteria: part a: * subjects with advanced or metastatic solid tumors who have either progressed on standard therapy or for whom standard therapy is not known part b: * subjects with advanced or metastatic gastroesophageal cancer, hrprc, hnscc, or prcc who have either progressed on standard therapy, or for whom standard therapy is not known. eighteen (18) subjects each with gastroesophageal cancer, hrprc, and hnscc will be treated. subjects with prcc (up to 18) will be enrolled as feasible * tumor paraffin tissue block or 6-10 unstained slides from the tumor tissue block must be provided * subjects with hrprc must have either measurable disease or rising psa levels (≥3 consecutive rising levels with at least 1 week interval and with psa level ≥5 mg/ml). all other subjects must have measurable disease as assessed by ct or mri exclusion criteria: * know brain metastases * uncontrolled or significant cardiovascular disease * retinal atrophy
patient education in the clinical management of pessary

Conditions: Pelvic Organ Prolapse

Summary: this study is a prospective, randomized, controlled, single-blinded, multi-center clinical trial. symptomatic patients with pelvic organ prolapse (pop) stage ii, iii or iv arranged to undergo pessary treatment will be randomized into either the experimental group or the control group. all patients will receive conventional verbal/paper instruction and counseling from a specialized doctor or nurse before pessary fitting, and the experimental group will receive additional patient education in the form of a re-watchable video. the video mainly includes a short introduction of pessary treatment for pelvic organ prolapse, tips and tricks for wearing and self-management of pessary, possible adverse reactions and remedy. all patients will receive regular pessary fitting and be followed up for 1 year. self-assessment questionnaires will be used to assess the patients' willingness to pessary treatment, anxiety status, treatment satisfaction and efficacy, and to assess the patients' self-management, complications and treatment adherence. then the differences between the two groups will be compared.


Eligibility criteria:
inclusion criteria: * symptomatic pelvic organ prolapse of stage ii\~iv * ability to participate in clinical trial and follow-up * the patient and family understand the study, are willing to participate in the 1-year study, and provide written informed consent exclusion criteria: * acute phase of infection of the internal and/or external genital tracts * genital fistula * suspected or untreated lower genital tract tumors * abnormally elevated intra-abdominal pressure (e.g., ascites, tumors) * life expectancy less than 1 year * cognitive or language communication disorders * unable to watch video (e.g., blindness)
study of multiple oral doses of odanacatib (mk0822) in healthy adults (0822-002)

Conditions: Osteoporosis

Summary: this study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (mk0822).


Eligibility criteria:
inclusion criteria: * subject is a male between the ages of 18 and 45 or a female less than or equal to 70 years of age * females must be past menopause * subject is a nonsmoker * subject is willing to avoid excessive alcohol consumption during the study and is willing to avoid alcohol entirely for 24 hours prior to drug administration and during pk sampling * subject is willing to refrain from consuming grapefruit or grapefruit juice exclusion criteria: * subject has a history of multiple/severe allergies to drugs or food * subject has donated blood within 4 weeks of starting the study * subject has a history of metabolic bone disease, urolithiasis, or bisphosphonate treatment * subject has any infections or any condition leading to immune problems, including hiv * subject regularly uses illegal drugs * subject consumes more than 3 alcoholic beverages per day * subject drinks 4 or more caffeinated beverages per day * subject uses any prescription or nonprescription medications
clinical outcomes of the freedom spinal cord stimulation (scs) system for the management of chronic back and leg pain

Conditions: Chronic Low Back Pain; Pain in Leg, Unspecified

Summary: this study evaluates the freedom scs (spinal cord stimulation) system for the treatment of chronic back and leg pain. patients who have been diagnosed with failed back surgery syndrome (fbss) will receive a stimulator device for treatment of their pain.


Eligibility criteria:
inclusion criteria: * appropriate freedom scs candidate as affirmed by study investigator * candidate has a stable spine not suitable for further surgery as confirmed by physician * 18 years of age or older (no upper age limit) * diagnosis of failed back surgery syndrome (fbss) characterized by chronic, intractable pain of the legs, back, or both legs and back * at least 6 months since last surgical procedure on the spine * average score of 60mm or greater on a vas scale (scale of 0 to 100, where 0 equals no pain and 100 equals worst possible pain) * pain duration of at least 6 months * expected lifespan of at least two years * able to comply with study requirements * gives informed consent for study participation exclusion criteria: * a consistent vas score of 100 over the past 24 hours as established at visit 1 * a co-existing condition that could increase the risk of scs implantation (e.g., severe cardiac or respiratory disorders, coagulation disorder) or planned surgery within the study duration that could be compromised by scs (e.g., diathermy) * pregnant or planning to become pregnant * known or suspected substance abuse within the last 2 years * major psychiatric disorder (untreated or refractory to treatment) in the investigators opinion * cognitive and/or behavioral issues that could impair study participation, (e.g., unreliability; defective memory; noncompliance in taking medications or keeping appointments; or impaired orientation to time, place, and events) * documented allergy to freedom scs material components * co-existing pain condition or participation in another clinical study that could confound the results of this study * history of another implanted medical device (e.g., explanted spinal cord stimulator, peripheral nerve stimulation, sacral nerve stimulator, pacemaker, or intrathecal drug delivery)
evaluation of cholesterol education for at-risk children

Conditions: Cardiovascular Diseases; Heart Diseases; Hypercholesterolemia; Coronary Heart Disease Risk Reduction

Summary: to evaluate two educational programs that promoted the role of pediatric practices in lowering ldl cholesterol levels in 4-10 year old hypercholesterolemic children through dietary modification.

background: outcomes of the study provided valuable guidance for pediatricians who wanted to become more actively involved in identifying and treating children with elevated blood lipids. design narrative: pediatricians in five practices in abington, pennsylvania conducted a cholesterol screening program (capillary bloodsample) for 4-10 year old children in their care. children who tested positive (total cholesterol \>176 mg/dl) were offered follow-up evaluations (two fasting venous blood samples) to confirm the positive initial test. those with mean ldl cholesterol levels between the 80th and 98th percentiles for age/sex (107-164 mg/dl for boys and 112-164 mg/dl for girls) and who met other entry criteria were invited to join the study. children with parental permission to participate were randomized to one of three groups: two that received dietary education, and a comparison group that received no dietary education. one educational program used face-to-face counseling with a registered dietitian and the other used a home-based, parent-child autotutorial approach. in addition, a random sample of non-hypercholesterolemic children with total plasma cholesterol levels between the 40th and 60th percentiles for age/sex were invited to join the study as a second comparison group. prior to the education period (baseline) and three times thereafter (3, 6 and 12 months post-baseline), all four groups were assessed for consumption of total fat, saturated fat, and cholesterol, and their growth and pertinent cognitive psychosocial factors. also, the plasma ldl cholesterol levels of the three hypercholesterolemic groups were assessed at all four time points along with blood indicators of iron status at baseline and twelve months. to assess the educational programs' effectiveness, changes were compared in assessed variables of the hypercholesterolemic groups who did and did not receive dietary education. also, changes in diet, growth, and cognitive/psychosocial factors in these groups were compared with those of the non-hypercholesterolemic group that had neither a positive diagnosis of elevated blood lipids nor dietary education. additionally, the cost-effectiveness of the two dietary education programs was evaluated. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
safety and efficacy study of panzem ncd to treat glioblastoma

Conditions: Recurrent Glioblastoma Multiforme

Summary: this single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of panzem (2-methoxyestradiol, 2me2) nanocrystal colloidal dispersion (ncd) administered in patients with recurrent glioblastoma multiforme (gbm)


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of a 1st or 2nd recurrent/progressive primary who grade iv malignant glioma (glioblastoma multiforme or gliosarcoma). * 18 years or older * an interval of at least 2 weeks between prior surgical resection or any major surgery or 4 weeks between prior radiotherapy or chemotherapy (except nitrosoureas which require 6 weeks) * karnofsky performance score equal to or greater than 70% * hematocrit greater than 29%, absolute neutrophil count greater than 1,500 cells/micro liters, platelets greater than 100,000 cells/ micro liters * serum creatinine less than 1.5 x upper limit of normal (uln), serum sgot less than 2.5 x uln; and bilirubin less than 1.5 times uln * signed informed consent form and authorization for use and disclosure of protected health information approved by the irb prior to patient entry * agree to use effective contraceptive methods exclusion criteria: * current, active systemic bleeding or excessive risk of bleeding * be pregnant or lactating; not employing effective birth control * concurrent severe and/or uncontrolled medical disease * impairment of gastrointestinal (gi) function/disease * requirement for therapy with coumadin (warfarin sodium) * patient is less than 5 years free of another primary malignancy * patients unwilling to or unable to comply with the protocol * grade 2 or greater peripheral sensory neuropathy